Sort by
Medicine and Dentistry
Neoplasm
100%
Acute Myeloid Leukemia
99%
Overall Survival
69%
Myelodysplastic Syndrome
58%
Diseases
48%
Multiple Myeloma
46%
Karyotype
38%
Fluorescence in Situ Hybridization
32%
B-Cell Lymphoma
30%
B-Cell Chronic Lymphocytic Leukemia
26%
Mantle Cell Lymphoma
26%
Diagnosis
24%
Chronic Myelogenous Leukemia
22%
Diffuse Large B-Cell Lymphoma
21%
Progression Free Survival
21%
Acute Lymphoblastic Leukemia
21%
Morphology
19%
Autologous Hematopoietic Stem Cell Transplantation
18%
Chronic Myelomonocytic Leukemia
18%
Myeloproliferative Neoplasm
17%
Malignant Neoplasm
17%
Venetoclax
17%
B Cell
17%
Tyrosine-Kinase Inhibitor
15%
Optical Genome Mapping
15%
Gene Mutation
14%
Chromosome Aberration
14%
MDS1 and EVI1 Complex Locus Protein
14%
Prognostic Factor
14%
Clinical Significance
14%
Anaplastic Large Cell Lymphoma
13%
Lymphoid Leukemia
13%
Cytotoxic Chemotherapy
12%
Acute Lymphocytic Leukemia
12%
Immunoglobulin Producing Cell
11%
Immunophenotyping
11%
Myeloma
11%
Hematopoietic Stem Cell Transplantation
11%
Myeloid Malignancy
11%
Stem Cell Transplant
11%
Rituximab
10%
Leukemia
10%
Core Binding Factor Beta
10%
Acute Leukemia
9%
Janus Kinase
9%
Cancer
9%
Disease Course
9%
Eosinophilia
9%
Precursor
8%
Risk Stratification
8%
Keyphrases
Acute Myeloid Leukemia
88%
Overall Survival
47%
Myelodysplastic Syndrome
40%
Chronic Myeloid Leukemia
39%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
39%
Chronic Lymphocytic Leukemia
32%
Fluorescence in Situ Hybridization
28%
Complex Karyotype
27%
Myeloid Neoplasms
26%
MYC Rearrangement
25%
Bone Marrow
24%
Poor Prognosis
22%
Mantle Cell Lymphoma
22%
Multiple Myeloma
21%
Venetoclax
21%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
B-cell Lymphoma 2 (Bcl-2)
18%
Tumor Protein p53 (TP53)
18%
Optical Genome Mapping
18%
Multiple Myeloma Patients
17%
Complete Remission
16%
TP53 mutation
15%
Newly Diagnosed
15%
Immunophenotyping
15%
Clinical Significance
15%
MECOM Rearrangement
15%
Myeloproliferative Neoplasms
14%
Anaplastic Large Cell Lymphoma
14%
High-grade B-cell Lymphoma
13%
Cytogenetic Abnormalities
13%
Progression-free Survival
13%
Immunophenotypic Profile
13%
Median Overall Survival
13%
Lymphoma Patients
13%
Leukemia Patients
12%
Relapsed or Refractory Acute Myeloid Leukemia
12%
ETV6
12%
Relapsed or Refractory
12%
KMT2A
12%
Double-hit Lymphoma
12%
MD Anderson Cancer Center
11%
Chemotherapy
11%
Therapy-related Myeloid Neoplasms
11%
Blast Phase
11%
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
10%
Acute Lymphoblastic Leukemia
10%
Disease Progression
10%
Tumor
10%
Prognostic Impact
10%
Diagnostic Challenge
10%
Biochemistry, Genetics and Molecular Biology
Myeloid
76%
Cytogenetics
68%
Overall Survival
52%
B Cell
37%
Karyotype
33%
Fluorescence in Situ Hybridization
32%
Optical Genome Mapping
19%
Progression Free Survival
18%
Immunophenotyping
15%
Gene Mutation
15%
Genomics
15%
Chromosomal Abnormalities
15%
Tyrosine Kinase Inhibitor
14%
Autologous Hematopoietic Stem Cell Transplantation
14%
T Cell
12%
Immunoglobulin Producing Cell
12%
ETV6
11%
Karyotyping
9%
Next Generation Sequencing
9%
Morphology
9%
Core Binding Factor Beta
9%
Philadelphia Chromosome
9%
Flow Cytometry
8%
Plasmacytoid Dendritic Cell
8%
MDS1 and EVI1 Complex Locus Protein
8%
Genetics
8%
KMT2A
8%
Chromosomal Aberration
7%
Precursor
7%
RNA Sequence
6%
Hematopoietic Cell
6%
Multivariate Analysis
5%
SF3B1
5%
Polysomy
5%
Cell Transplantation
5%
CD34
5%